MedTrace Logo

Symptomatic Treatment of Vascular Cognitive Impairment

NCT02098824 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2016-05-02

No results posted yet for this study

Summary

Single center threeway double blind cross over trial investigating the pharmacological responsivity in patients with VCI using a challenge aimed at the monoaminergic and cholinergic neuronal systems

Conditions

  • Mild Cognitive Impairment (Vascular)
  • Mild Cognitive Disorder (Vascular)
  • Vascular Dementia

Interventions

DRUG

Galantamine

Single administration of capsule containing 16 mg of Galantamine

DRUG

Methylphenidate

Single administration of capsule containing 10 mg of Methylphenidate

DRUG

Placebo

Single administration of capsule containing placebo

Sponsors & Collaborators

  • Amsterdam UMC, location VUmc

    lead OTHER

Principal Investigators

  • Niels D Prins, MD, PhD · VUmc

Study Design

Allocation
RANDOMIZED
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-02-28
Primary Completion
2016-12-31
Completion
2017-07-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02098824 on ClinicalTrials.gov